{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:24:55Z","timestamp":1761218695964,"version":"3.28.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Tianjin Key Medical Discipline(Specialty) Construction Project","award":["TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A","TJYXZDXK-009A"]}]},{"name":"Liang Liu","award":["Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487"],"award-info":[{"award-number":["Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487","Nature Science Foundation of China :81872487"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13084-x","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:12:00Z","timestamp":1730193120000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation"],"prefix":"10.1186","volume":"24","author":[{"given":"Yanjuan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingge","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"13084_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"13084_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367\u201380.","journal-title":"N Engl J Med"},{"key":"13084_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2019;135:196\u2013204.","journal-title":"Lung Cancer"},{"key":"13084_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1586\/14737140.2016.1170596","volume":"16","author":"A Rossi","year":"2016","unstructured":"Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16:653\u201360.","journal-title":"Expert Rev Anticancer Ther"},{"key":"13084_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JOP.2015.008524","volume":"12","author":"GA Masters","year":"2016","unstructured":"Masters GA, Johnson DH, Temin S. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice guideline update. J Oncol Pract. 2016;12:90\u20133.","journal-title":"J Oncol Pract"},{"key":"13084_CR6","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192\u2013237.","journal-title":"Ann Oncol"},{"key":"13084_CR7","doi-asserted-by":"publisher","first-page":"e001492","DOI":"10.1136\/bmjresp-2022-001492","volume":"10","author":"U Batra","year":"2023","unstructured":"Batra U, Biswas B, Prabhash K, Krishna MV. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res. 2023;10:e001492.","journal-title":"BMJ Open Respir Res"},{"key":"13084_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","volume":"15","author":"G Recondo","year":"2018","unstructured":"Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694\u2013708.","journal-title":"Nat Rev Clin Oncol"},{"key":"13084_CR9","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.","journal-title":"N Engl J Med"},{"key":"13084_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"13084_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u201322.","journal-title":"Lancet Oncol"},{"key":"13084_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"13084_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7888\/juoeh.41.153","volume":"41","author":"K Yoneda","year":"2019","unstructured":"Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell Lung Cancer with EGFR-mutations. J UOEH. 2019;41:153\u201363.","journal-title":"J UOEH"},{"key":"13084_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1200\/JCO.19.01488","volume":"38","author":"Y Hosomi","year":"2020","unstructured":"Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38:115\u201323.","journal-title":"J Clin Oncol"},{"key":"13084_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625\u201335.","journal-title":"Lancet Oncol"},{"key":"13084_CR16","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12943-023-01823-w","volume":"22","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wang L, Wang J, Chen J, Meng Z, Liu Z, et al. Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study. Mol Cancer. 2023;22:124.","journal-title":"Mol Cancer"},{"key":"13084_CR17","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1038\/s41467-021-26806-7","volume":"12","author":"SY Liu","year":"2021","unstructured":"Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, et al. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nat Commun. 2021;12:6450.","journal-title":"Nat Commun"},{"key":"13084_CR18","first-page":"3159","volume":"18","author":"Y Liu","year":"2019","unstructured":"Liu Y, Xu F, Wang Y, Wu Q, Wang B, Yao Y, et al. Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. Oncol Lett. 2019;18:3159\u201369.","journal-title":"Oncol Lett"},{"issue":"2","key":"13084_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cllc.2020.11.001","volume":"22","author":"XM Li","year":"2021","unstructured":"Li XM, Li WF, Lin JT, et al. Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI: analysis of a phase III randomized clinical trial (CTONG 0901). Clin Lung Cancer. 2021;22(2):100\u20139.","journal-title":"Clin Lung Cancer"},{"doi-asserted-by":"crossref","unstructured":"Aggarwal C, Davis CW, Mick R et al. Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer. JCO Precis Oncol. 2018;2018:PO.18.00107.","key":"13084_CR20","DOI":"10.1200\/PO.18.00107"},{"key":"13084_CR21","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale M, Petracci E, Delmonte A, Chiadini E, Dazzi C, Papi M, et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin Cancer Res. 2017;23:2195\u2013202.","journal-title":"Clin Cancer Res"},{"key":"13084_CR22","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552\u201361.","journal-title":"N Engl J Med"},{"key":"13084_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.18632\/genesandcancer.145","volume":"8","author":"T Kurata","year":"2017","unstructured":"Kurata T, Nakaya A, Yokoi T, Niki M, Kibata K, Takeyasu Y, et al. Phase I\/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-na\u00efve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation. Genes Cancer. 2017;8:559\u201365.","journal-title":"Genes Cancer"},{"key":"13084_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s10637-017-0527-z","volume":"36","author":"M Tamiya","year":"2018","unstructured":"Tamiya M, Tamiya A, Shiroyama T, Takeoka S, Naito Y, Omachi N, et al. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-na\u00efve advanced non-squamous non-small cell lung cancer with EGFR mutations. Invest New Drugs. 2018;36:608\u201314.","journal-title":"Invest New Drugs"},{"key":"13084_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-3-319-91442-8_16","volume":"211","author":"J Rawluk","year":"2018","unstructured":"Rawluk J, Waller CF. Gefitinib. Recent Results Cancer Res. 2018;211:235\u201346.","journal-title":"Recent Results Cancer Res"},{"key":"13084_CR26","doi-asserted-by":"publisher","first-page":"175883591989165","DOI":"10.1177\/1758835919891652","volume":"11","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zeng K, Zhao S, Zhao Y, Hou X, Luo F, et al. Pemetrexed\/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced non small cell lung cancer: a Bayesian network meta-analysis. Ther Adv Med Oncol. 2019;11:1758835919891652.","journal-title":"Ther Adv Med Oncol"},{"key":"13084_CR27","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.21.02911","volume":"40","author":"E Miyauchi","year":"2022","unstructured":"Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol. 2022;40:3587\u201392.","journal-title":"J Clin Oncol"},{"key":"13084_CR28","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1200\/JCO.2016.66.9218","volume":"34","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34:3258\u201366.","journal-title":"J Clin Oncol"},{"key":"13084_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","volume":"38","author":"V Noronha","year":"2020","unstructured":"Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124\u201336.","journal-title":"J Clin Oncol"},{"key":"13084_CR30","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"key":"13084_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11864-016-0394-4","volume":"17","author":"TE Stinchcombe","year":"2016","unstructured":"Stinchcombe TE. The use of EGFR tyrosine kinase inhibitors in EGFR wild-type non-small-cell lung cancer. Curr Treat Options Oncol. 2016;17:18.","journal-title":"Curr Treat Options Oncol"},{"key":"13084_CR32","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00432-020-03228-4","volume":"146","author":"A Li","year":"2020","unstructured":"Li A, Cao W, Liu X, Zhang Y, Ma Y, Xu R, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020;146:1737\u201349.","journal-title":"J Cancer Res Clin Oncol"},{"key":"13084_CR33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"13084_CR34","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1634\/theoncologist.2011-0385","volume":"17","author":"ZY Chen","year":"2012","unstructured":"Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist. 2012;17:978\u201385.","journal-title":"Oncologist"},{"key":"13084_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13084-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13084-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T06:56:41Z","timestamp":1730271401000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13084-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13084"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13084-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethical Institution Tianjin Medical University Cancer Committee and Hospital (approval number: E20210961, date: 2021-11-26). Informed consent was obtained from all individual participants included in the study. The consent process was documented through written consent forms, and participants were ensured about the confidentiality of their data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1326"}}